Actively Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Led by Complement Therapeutics · Updated on 2026-05-04
75
Participants Needed
9
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. This is a multi-center, non-interventional, observational study which aims to identify participants who have progressive GA to allow quantification of structural and functional parameters that characterize the progression of GA, and to investigate whether these correlate with genetic or lifestyle factors.
CONDITIONS
Official Title
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be aged 6555 years at the time of informed consent
- Participants with bilateral geographic atrophy secondary to age-related macular degeneration confirmed by Central Reading Center
- At least one eye must have total GA lesion area between 1.25 mm2 and 17.5 mm2 inclusive as determined by fundus autofluorescence imaging
- Best-corrected visual acuity (BCVA) in both eyes sufficient for navigational vision (20/400 or better)
- BCVA between 20 and 75 letters and low-luminance visual acuity (LLVA) greater than 0 letters using an ETDRS chart
- Mean retinal sensitivity of 5 dB or greater as measured by microperimetry using the study grid
- Able and willing to provide signed informed consent and perform all study assessments
You will not qualify if you...
- Macular atrophy secondary to conditions other than age-related macular degeneration in the study eye
- Any macular pathology other than GA secondary to AMD or changes consistent with early, intermediate, or atrophic AMD in the study eye
- Evidence of prior or current choroidal neovascularization (wet AMD) in either eye
- Atrophic retinal diseases other than AMD including monogenetic macular dystrophies, myopia-related maculopathy, and Stargardt disease in the study eye
- History of vitrectomy in the study eye
- Prior treatment for AMD or intravitreal treatment except oral vitamin and mineral supplements like AREDS formula
- Any intraocular surgery (except cataract surgery within 6 months) or thermal laser within 3 months before screening
- Any macular laser, macular surgery, or retinal surgery at any time in the study eye
- Ocular or periocular infection within 12 weeks before screening
- History of uveitis or endophthalmitis in either eye
- Signs of diabetic retinopathy or HbA1c greater than 8 in the 12 months before enrollment
- High myopia or hyperopia (6 diopters or more) in the study eye
- Uncontrolled intraocular pressure over 25 mmHg for more than 1 month despite treatment, or glaucomatous damage
- Retinal diseases other than AMD or ocular disorders causing safety concerns per investigator judgment
- Ophthalmologic conditions reducing clarity of media or preventing adequate retinal imaging
- Aphakia or absence of posterior capsule unless due to YAG laser posterior capsulotomy at least 60 days prior
- Medical or psychiatric conditions making follow-up unlikely or poor medical risk
- Participation in interventional clinical study or experimental AMD treatment within 6 months or 5 half-lives
- Clinically significant abnormal lab tests at enrollment
- Hypersensitivity to medications used in study procedures
- Investigator judgment that risk of harm outweighs potential benefit
- History or current use of medications associated with macular changes or optic nerve damage
- Previous gene or cell therapy
- Use of chloroquine, hydroxychloroquine, platinum drugs, ethambutol, tamoxifen, pentosan, chronic phosphodiesterase inhibitors, or GLP-1 antagonists in crowded optic disc setting
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Northern California Retina Vitreous Associates Medical Group
Mountain View, California, United States, 94040
Actively Recruiting
2
Midwest Eye Institute
Carmel, Indiana, United States, 46032
Actively Recruiting
3
Sierra Eye Associates
Reno, Nevada, United States, 89502
Actively Recruiting
4
Mid Atlantic Retina
Bethlehem, Pennsylvania, United States, 18017
Actively Recruiting
5
Retina Foundation of the Southwest
Dallas, Texas, United States, 75231
Actively Recruiting
6
Gundersen Health System
La Crosse, Wisconsin, United States, 54601
Actively Recruiting
7
Gloucestershire Royal Hospital
Gloucester, Gloucester, United Kingdom, GL1 3NN
Actively Recruiting
8
Moorfields Eye Hospital
London, London, United Kingdom, EC1V 2PD
Actively Recruiting
9
The Retina Clinic London
London, United Kingdom, W1G 7LB
Actively Recruiting
Research Team
M
Muhammad Ali Memon
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here